Discontinued drugs in 2006: central and peripheral nervous system drugs.
This perspective describes compounds that target the central and peripheral nervous system, whose development was discontinued in 2006 and which were being developed for the treatment of a range of neurological disorders, including chronic pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy and anxiety. These discontinued candidates are described by disease area, based on information available from the Pharmaprojects database.
Collins
Susanne D
SD
Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK. Sue.D.Collins@gsk.co.uk
D000818:Animals; D002491:Central Nervous System Agents / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy; D017211:Treatment Failure
D002491:Central Nervous System Agents; D015507:Drugs, Investigational